Satellos Bioscience Inc.
NGM: MSLELive Quote
📈 ZcoreAI Score
Our AI model analyzes Satellos Bioscience Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MSLE Z-Score →About Satellos Bioscience Inc.
Healthcare
Biotechnology
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
📊 Fundamental Analysis
Satellos Bioscience Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -66.4%, which indicates that capital utilization is currently under pressure.
At a current price of $6.50, MSLE currently sits at the 22nd percentile of its 52-week range (Range: $4.52 - $13.39).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$135.91M
Trailing P/E
--
Forward P/E
-1.95
Beta (5Y)
1.08
52W High
$13.39
52W Low
$4.52
Avg Volume
77K
Day High
Day Low